Form 4: Corcept CSO Exercises Options, Sells Shares

Corcept Therapeutics' Chief Scientific Officer, Hazel Hunt, exercised stock options and subsequently sold shares to cover the exercise cost and tax obligations.

Summary

• Hazel Hunt, Chief Scientific Officer of Corcept Therapeutics Inc. (CORT), engaged in transactions involving company common stock.
• On February 9, 2026, Hunt exercised stock options to acquire 150,000 shares of common stock at an exercise price of $3.88 per share.
• Concurrently, 77,968 shares were disposed of at a price of $41.31 per share to satisfy the exercise price and tax withholding obligations related to a net (cashless) exercise of stock options.
• Following these transactions, Hunt directly owns 255,437 shares of Corcept Therapeutics common stock.
• The stock options exercised were fully exercisable and set to expire on February 26, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects an executive realizing value from long-held options, which is a normal part of compensation, without indicating a significant change in sentiment towards the company.

Positives

• The exercise of options indicates a significant in-the-money position for the Chief Scientific Officer, as the exercise price was $3.88 while the shares were disposed of at $41.31.
• The transaction represents a standard liquidity event for an executive exercising expiring options.

Negatives

• The sale of 77,968 shares, even if for tax and exercise cost coverage, reduces the direct beneficial ownership of the Chief Scientific Officer.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider transactions like option exercises and subsequent sales for tax purposes are common occurrences in the biotechnology and pharmaceutical sectors, reflecting executive compensation structures and personal financial planning.

Comparison to Industry Standards

• This type of transaction is standard for executives in publicly traded companies across various industries, particularly when stock options are nearing expiration and are significantly in-the-money. There are no specific comparable companies or projects mentioned in this Form 4.

Related Party Transactions

• The reported transactions involve an officer of Corcept Therapeutics Inc. (Hazel Hunt) and company securities, which constitutes a related party dealing.

Stakeholder Impact

• Shareholders: The sale of shares by an insider, even for tax purposes, slightly increases the float but is generally not seen as a negative signal when tied to option exercise. The underlying value realized by the CSO could be seen as a positive for executive retention.

Key Dates

Recommendation

This Form 4 details a routine insider transaction where the Chief Scientific Officer exercised expiring stock options and sold a portion of the acquired shares to cover the exercise price and tax liabilities. Such transactions are common and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. The significant spread between the exercise price and the disposition price indicates the options were deeply in-the-money, reflecting past stock performance. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Corcept Therapeutics, CORT, Hazel Hunt, Chief Scientific Officer, Stock Options, Insider Trading, Form 4, Equity Compensation, Executive Compensation, Share Sale